Package Leaflet: Information for the User
Solifenacin Succinate Qilu5mg Film-Coated Tablets EFG
solifenacin succinate
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the Pack
The active substance in Solifenacin Succinate Qilu belongs to a group of medicines called anticholinergics. These medicines are used to reduce the activity of an overactive bladder. This allows you to wait longer before you need to urinate and increases the amount of urine you can hold in your bladder.
This medicine is used to treat the symptoms of a condition called overactive bladder, which include: having a sudden, urgent need to urinate without prior warning, having to urinate frequently, or having involuntary leakage of urine.
Do not take Solifenacin Succinate Qilu:
Before starting treatment with Solifenacin Succinate Qilu, tell your doctor if you have or have had any of the disorders described above.
Warnings and Precautions
Consult your doctor or pharmacist before starting Solifenacin Succinate Qilu if:
Before starting Solifenacin Succinate Qilu, tell your doctor if you have or have had any of the disorders described above.
Before starting treatment with Solifenacin Succinate Qilu, your doctor will assess whether there are other causes for your frequent need to urinate, such as heart failure (insufficient heart pumping capacity) or kidney disease. If you have a urinary tract infection, your doctor will prescribe an antibiotic (treatment for certain bacterial infections).
Children
This medicine must not be used in children.
Other Medicines and Solifenacin Succinate Qilu
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
It is very important that you inform your doctor if you are taking:
Pregnancy and Breastfeeding
Do not take this medicine if you are pregnant, unless your doctor considers it necessary. Do not take this medicine if you are breastfeeding, as it may pass into breast milk.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and Using Machines
This medicine may cause blurred vision and, occasionally, drowsiness or fatigue. If you experience any of these effects, do not drive or use machines.
Solifenacin Succinate Qilu contains Lactose Monohydrate
If your doctor has told you that you have an intolerance to some sugars, consult them before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
The recommended dose is 5 mg once daily, unless your doctor has told you to take 10 mg once daily.
Swallow the tablet whole with a little water. You can take it with or without food, as you prefer. Do not crush the tablets.
If you take more Solifenacin Succinate Qilu than you should
If you have taken more Solifenacin Succinate Qilu than you should, talk to a doctor or pharmacist immediately or go to the nearest hospital casualty department. Take the medicine pack with you.
Symptoms of overdose may include: headache, dry mouth, dizziness, drowsiness, and blurred vision, perceiving things that do not exist (hallucinations), overexcitement, seizures (convulsions), difficulty breathing, rapid heartbeat (tachycardia), urine accumulation in the bladder (urinary retention), and dilated pupils (mydriasis).
If you forget to take Solifenacin Succinate Qilu
If you forget to take a dose at the usual time, take it as soon as you remember, unless it is nearly time for your next dose. Do not take a double dose to make up for a forgotten dose.
If you stop taking Solifenacin Succinate Qilu
If you stop taking this medicine, the symptoms of overactive bladder that you are experiencing may come back or get worse. If you are considering stopping treatment, consult your doctor.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you experience a severe allergic reaction or a severe skin reaction (e.g., blisters and peeling of the skin), contact your doctor or pharmacist immediately.
In some patients treated with solifenacin succinate, cases of angioedema (an allergic reaction of the skin that causes inflammation of the tissues under the skin surface) accompanied by respiratory tract obstruction (difficulty breathing) have been reported. If you experience any symptoms of angioedema, stop taking this medicine and contact your doctor immediately.
Other side effects:
Very Common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Very Rare(may affect up to 1 in 10,000 people)
Frequency Not Known(frequency cannot be estimated from the available data)
Reporting of Side Effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Store below 25°C. Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
Bottles of 30, 90, and 100 tablets: once opened, the tablets can be stored for 3 months. Keep the bottle tightly closed.
Bottles of 2000 tablets: once opened, the tablets can be stored for 6 months. Keep the bottle tightly closed.
Do not use this medicine if you notice that the packaging is damaged or shows signs of deterioration.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Solifenacin Succinate Qilu
Each film-coated tablet contains 5 mg of solifenacin succinate, equivalent to 3.8 mg of solifenacin.
Core of the tablet: lactose monohydrate, corn starch, hypromellose (5 cps), magnesium stearate.
Coating: talc, hypromellose (6 cps), macrogol 8000, titanium dioxide (E-171), yellow iron oxide (E-172).
Appearance and Packaging
Film-coated tablets, round, light yellow in color, and engraved with «23» on one side.
Solifenacin succinate film-coated tablets are available in blisters of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, and 200 tablets and in bottles of 30, 90, 100, and 2000 tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Qilu Pharma Spain S.L.
Paseo de la Castellana, 40,
8th floor, 28046 Madrid
Spain
Manufacturer:
KYMOS PHARMA SERVICES, S.L.,
Ronda de Can Fatjó,
7B (Parque Tecnológico del Vallès),
Cerdanyola del Vallès,
08290-Barcelona,
Spain
NETPHARMALAB CONSULTING SERVICES
Carretera de Fuencarral 22,
Alcobendas, Madrid -28108
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
United Kingdom | Solifenacin succinate 5 mg film-coated tablets |
Germany | Solifenacinsuccinat Qilu 5 mg Filmtabletten |
Spain | Solifenacina succinato Qilu 5 mg film-coated tablets EFG |
France | SOLIFENACINE QILU 5 mg, film-coated tablet |
Date of Last Revision of this Leaflet:February 2019.
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/